Delivery Order SPE2DB24D2106-SPE2DB26FATVW
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on July 29, 2025, for the supply of Atovaquone-Proguanil 250-100 tablets (100 count). This firm fixed-price delivery order, valued at $1,667.64, represents a single-line item procurement with a completion deadline of July 30, 2025. The award carries no set-aside designation, allowing the vendor to compete in...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,929.98 firm fixed-price delivery order is for the supply of atovaquone and proguanil, a prescription antimalarial medication. DMS Pharmaceutical Group holds a large $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to place delivery...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,953.32 to DMS Pharmaceutical Group Inc. for the supply of Malarone 250-100 mg tablets (100-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its primary location. The contract was awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, and no set-aside designation was...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,640.08 firm fixed-price delivery order is for the supply of Atovaquone-Proguanil 250-100 100s, a pharmaceutical product. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain organization, awarded a delivery order to DMS Pharmaceutical Group Inc. for supply of Malarone 250-100 mg tablets (100-count units) with a ceiling value of $2,680.67. This firm fixed-price delivery order, issued on April 24, 2025, represents a continuation of the agency's pharmaceutical procurement under its existing indefinite delivery contract vehicle. DMS Pharmaceutical Group Inc., a woman-owned small business...
- DMS Pharmaceutical Group Inc. has been awarded a $501 firm fixed price delivery order against the Defense Logistics Agency's Pharmaceutical Prime Vendor contract to supply 100 units of 250-100mg tablets of atovaquone-proguanil by October 21, 2022. The order was issued on October 20 by the Defense Logistics Agency without a set-aside designation to meet demand for this antimalarial medication. Performance will occur in Park Ridge, Illinois. No major subcontractors were identified. This delivery...
- The Defense Logistics Agency Troop Support Medical has awarded a firm-fixed-price delivery order contract valued at $9,725.94 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This order is against DMS Pharmaceutical Group's existing indefinite delivery contract 4600082013 under the DLA's SPE2DB program, which has a potential total value of up to $4,999,999 through 2025. The current delivery order is for 4,563,723,318...
- The U.S. government's Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract worth $1,390.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of ATOVAQUONE/PROGUANIL, a pharmaceutical product, and does not have a set-aside designation. This delivery order contract is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,250.73 contract is for the delivery of 4,567,951,594 units of Atovaquone-Proguanil 250-100 100s, a prescription medication. The contract has an ultimate completion date of April 18, 2025 and was awarded on April 17, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $2,067.00 and has a completion date of June 26, 2024. DMS Pharmaceutical Group will supply the DLA with 4564993076 units of Atovaquone-Proguanil 250-100mg tablets. This delivery order is issued under a larger indefinite delivery...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB26FATVWDelivery Order
The Defense Logistics Agency awarded a $5,502.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 100 units of Atovaquone-Proguanil 250-100, an antimalarial medication used for malaria prophylaxis and treatment. The award, issued on October 17, 2025, with an ultimate completion date of October 20, 2025, carries no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in unrestricted federal procurement. Performance will occur in Conshohocken, Pennsylvania. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy established to supply pharmaceutical products and medical consumables to Department of Defense military healthcare facilities worldwide. The underlying IDC, awarded November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period followed by three 30-month option periods. DMS Pharmaceutical Group has demonstrated substantial contracting activity as a critical supplier within the federal pharmaceutical supply chain, delivering diverse products ranging from routine pharmaceuticals to specialty biologics and vaccines to support recurring military medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 10/17/25 |